Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) reported Q1 FY2022 results with revenues of $4,995 million, down 6% from the previous year. Base revenues rose 8.1%, driven by strong performance in BD Medical, which grew 6% to $2,397 million. However, the BD Life Sciences segment saw a significant decline of 25% due to lower COVID-19 testing revenues. The company raised its FY2022 revenue guidance to $19.55-$19.75 billion and adjusted EPS to $12.80-$13.00. BD continues to focus on innovation, M&A, and ESG initiatives, while also navigating currency headwinds.
On February 1, 2022, BD (Becton, Dickinson and Company) announced its board of directors approved the spinoff of its diabetes care business, set to become Embecta Corp. The spinoff will take effect on April 1, 2022, with BD shareholders receiving one share of Embecta stock for every five shares of BD owned by March 22, 2022. The move aims to sharpen BD's focus on its core growth strategies and enhance Embecta's capacity for capital attraction and innovation in diabetes management. The IRS has deemed the transaction tax-free for U.S. federal income tax purposes.
BD (Becton, Dickinson and Company) has acquired Cytognos, a Spanish firm specializing in flow cytometry solutions for blood cancer diagnostics. This move enhances BD’s portfolio by integrating advanced assays for monitoring minimal residual disease (MRD) and improving cancer care. Cytognos brings over 25 years of expertise, complementing BD’s existing products and expanding its reach in chronic disease management. The acquisition, expected to be immaterial to BD's fiscal 2022 results, strengthens existing collaborations with the EuroFlow Consortium.
BD (Becton, Dickinson and Company) announced a peer-reviewed study in Obstetrics & Gynecology highlighting the effectiveness of molecular diagnostics in diagnosing vaginitis. The study found that clinician assessments missed 45.3% of positive cases and incorrectly identified 12.3% of negative cases. With vaginitis affecting 6 to 10 million women annually in the U.S., this study emphasizes the need for accurate diagnostic tools. The BD MAX™ Vaginal Panel Assay provides quicker and more accurate results, enhancing treatment decisions for patients.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share. This dividend is scheduled for payment on March 31, 2022, to shareholders of record as of March 10, 2022. The indicated annual dividend rate stands at $3.48 per share, reflecting BD's commitment to returning value to its shareholders.
BD (Becton, Dickinson and Company) announced a significant advancement in flow cytometry through its new BD CellView™ Image Technology, highlighted in the journal Science. This technology allows for the sorting of individual cells at speeds of up to 15,000 cells per second, integrating fluorescence imaging for enhanced analysis. The system captures detailed images, enabling precise identification of biomarkers and their distributions, which could accelerate research in immunology and genomics. The technology promises to transform cell-based therapeutic discovery, filling long-standing gaps in biomedical research.
BD (Becton, Dickinson and Company) announces a collaboration with Pfizer and Wellcome to enhance antimicrobial stewardship through improved diagnostic practices. This initiative aims to identify gaps in current diagnostic testing related to antimicrobial resistance (AMR), which poses a significant global health challenge, potentially leading to 10 million deaths annually by 2050. Experts emphasize the need for better diagnostic tools and education to combat AMR effectively. The COVID-19 pandemic has highlighted the importance of diagnostics in managing antibiotic use.
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its BD Kiestra™ IdentifA system, aimed at automating microbiology bacterial identification testing. This automated system utilizes BD Synapsys™ informatics and robotics to enhance accuracy and efficiency, reducing human error in sample preparation. The BD Kiestra™ IdentifA is notable for being the only FDA-cleared solution integrated into a track-connected lab automation system. This innovation seeks to improve patient management by accelerating pathogen identification, thereby supporting better clinical decision-making.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
